Stimulation of both CCK-A and CCK-B receptors activates MAP kinases in AR42J and receptor-transfected CHO cells.
It was recently found that cholecystokinin (CCK) activates mitogen-activated protein kinases (MAPK) in isolated rat pancreatic acini. The present study evaluates whether one or both types of CCK receptors are capable of MAPK activation in pancreatic AR42J acinar cells as well as CHO cells transfected with CCK-A or CCK-B receptors. CCK significantly increased p44 MAPK and p42 MAPK activities in AR42J cells. Minimal, half-maximal, and maximal responses were observed at 30 and 500 pM and 10 nM, respectively, after CCK-8 stimulation and at 100 pM and 1.5 and 30 nM, respectively, after gastrin stimulation. Glycine-extended gastrin had no effect at 100 nM and a small but significant effect at 1 microM. The CCK-B receptor antagonist L365,260 almost totally blocked MAPK activation in AR42J cells after stimulation with gastrin and glycine-extended gastrin and substantially reduced the activation of both kinases by CCK-8, while the CCK-A receptor antagonist L364,718 was much less effective. The CCK-A-selective agonist A71376, however, was an effective stimulant of MAPK activity. In an alternative approach, stably transfected CHO cells bearing either CCK-A or CCK-B receptors were stimulated with CCK-8. Each receptor induced a time-dependent increase in activity of both MAPKs by five- to sixfold in CCK-A- and CCK-B-bearing cells. In conclusion, both CCK-A and CCK-B receptors activate MAPK in AR42J cells and in transfected CHO cells.
Dabrowski
A
A
Department of Physiology, University of Michigan, Ann Arbor 48109-0622, USA.
Detjen
K M
KM
Logsdon
C D
CD
Williams
J A
JA
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D015153:Blotting, Western; D016466:CHO Cells / Q000187:drug effects / Q000378:metabolism; D018267:Carcinoma, Acinar Cell / Q000503:physiopathology; D002478:Cells, Cultured; D006224:Cricetinae; D020109:Devazepide; D004305:Dose-Response Relationship, Drug; D005755:Gastrins / Q000494:pharmacology; D048768:MAP Kinase Kinase Kinase 4; D020930:MAP Kinase Kinase Kinases; D009842:Oligopeptides / Q000494:pharmacology; D010190:Pancreatic Neoplasms / Q000503:physiopathology; D010671:Phenylurea Compounds; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*; D012016:Reference Values; D012844:Sincalide / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D001570:Benzodiazepinones; D005755:Gastrins; D009842:Oligopeptides; D010671:Phenylurea Compounds; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C063897:A 71378; C058121:L 365260; D011494:Protein Kinases; D048768:MAP Kinase Kinase Kinase 4; D020930:MAP Kinase Kinase Kinases; D020109:Devazepide; D012844:Sincalide